Urethral Cancer - Symptoms, Diagnosis, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Urethral cancer is the rarest genitourinary malignancy, accounting for less than 1% of all urological malignancies in the United States, with approximately 600 new cases diagnosed per year. Despite the rarity, it carries significant morbidity due to late-stage presentation, challenges in achieving local control, and the anatomically sensitive location requiring complex surgical or radiotherapy approaches that can impact continence and sexual function. Three main histological types reflect the different zones of urethral epithelium: squamous cell carcinoma (SCC) predominates in the distal urethra and accounts for approximately 50-80% of cases across sexes; transitional cell (urothelial) carcinoma arises in the proximal urethra (particularly in males where it is contiguous with bladder urothelium) and accounts for approximately 10-20%; and adenocarcinoma (arising from periurethral glands of Skene or Cowper's glands) accounts for approximately 10-15%, predominantly in females. Despite the anatomical differences between the male (approximately 20 cm) and female (approximately 4 cm) urethra, women are affected approximately 3-4 times more frequently than men relative to population size, likely reflecting differences in HPV-related carcinogenesis and urethral anatomy. Prognosis is critically determined by tumour location within the urethra — anterior (distal) tumours have substantially better outcomes than posterior (proximal) tumours.

The aetiology of urethral cancer varies by histological subtype and reflects different carcinogenic pathways. For squamous cell carcinoma of the urethra, the most important risk factors are chronic local irritation and HPV infection. HPV-16 is implicated in anterior urethral SCC in both sexes; other sexually transmitted infections including gonorrhoea and chlamydia trachomatis cause chronic urethritis and fibrous stricture, creating a chronic inflammatory carcinogenic microenvironment. Urethral stricture disease — from any cause including instrumentation, catheterisation, trauma, or recurrent STIs — is a recognised risk factor as it causes chronic mucosal irritation and stasis of urine. Urethral diverticulum — a sac-like outpouching of the urethral wall, predominantly in women — is strongly associated with urethral adenocarcinoma developing within the diverticulum. Prior pelvic radiotherapy (for cervical, prostate, or rectal cancer) is a risk factor for secondary urethral malignancy. For transitional cell carcinoma of the urethra, risk factors overlap with bladder cancer: tobacco smoking, occupational chemical exposures (aromatic amines, benzidine), and urothelial field change from synchronous or previous bladder cancer are the dominant factors. Bladder cancer patients treated with cystectomy and urethral preservation have a 5-15% risk of urethral recurrence and require urethral surveillance.

The symptoms of urethral cancer are frequently non-specific and closely mimic benign conditions, contributing to the characteristic diagnostic delay of 6-24 months that results in the majority of patients presenting with locally advanced or metastatic disease. Haematuria (visible or microscopic blood in urine) is the most common initial symptom and should always be investigated in any adult, regardless of age. Dysuria (pain or burning during urination), urinary frequency and urgency, and urinary outflow obstruction (hesitancy, poor stream, urinary retention) reflect the anatomical obstruction caused by a growing intraurethral mass. Urethral discharge — watery, blood-tinged, or purulent — is a presenting symptom in females with anterior urethral tumours. A palpable urethral or periurethral mass may be detected on careful physical examination, particularly in females where the urethra is accessible on anterior vaginal wall examination. Perineal pain, pelvic pain, or pain during sexual intercourse may occur with posterior or deeply invasive tumours. Urethrovaginal fistula formation — with leakage of urine through the vagina — indicates advanced disease with fistulous communication between tumour-invaded urethra and vagina. Inguinal lymphadenopathy indicates regional spread from anterior urethral tumours (which drain to superficial inguinal nodes), while pelvic lymphadenopathy indicates spread from proximal urethral tumours (draining to pelvic and obturator nodes).

Urethroscopy with directed biopsy of any suspicious lesion is the definitive diagnostic procedure, providing tissue for histological subtyping and grading. Bimanual examination under anaesthesia assesses tumour fixation and adjacent organ involvement. MRI of the pelvis with dedicated high-resolution sequences provides the best soft tissue delineation of tumour extent, invasion depth through the urethral wall, involvement of the sphincter mechanism, corpus spongiosum (in males), vaginal wall (in females), and adjacent pelvic organs — critical for surgical planning and organ-preservation decisions. CT of the chest, abdomen, and pelvis with intravenous contrast is the standard staging modality to assess pelvic and retroperitoneal lymph nodes and distant metastases. PET/CT with 18F-FDG may be useful for staging in selected cases, particularly for evaluation of pelvic and inguinal nodal disease. Clinical TNM staging is based on depth of invasion through the urethral wall layers (T1: subepithelial connective tissue; T2: corpus spongiosum, periurethral muscle; T3: corpus cavernosum, anterior vaginal wall, bladder neck; T4: other adjacent organs). HPV genotyping guides prognosis for SCC. Urine cytology and cystoscopy are performed to exclude concomitant bladder urothelial carcinoma.

Treatment strategy for urethral cancer is guided by tumour location (anterior versus posterior), T stage, N stage, and histological type. For anterior urethral cancers (distal urethra, better prognosis): small, low-stage (T1-T2) distal tumours in males may be managed with local excision, partial urethrectomy, or laser ablation with intent to preserve the remaining urethra. Brachytherapy (interstitial implants) or external beam radiotherapy alone achieves organ preservation for selected small distal urethral SCCs. For proximal (posterior/bulbomembranous in males; proximal/bladder neck in females) or high-stage (T3-T4) urethral cancers: neoadjuvant cisplatin-based combination chemotherapy (typically gemcitabine-cisplatin or M-VAC) is given to downstage disease and control micrometastases before planned radical surgery; radical cystourethrectomy (in both sexes) with bilateral pelvic lymph node dissection and urinary diversion (ileal conduit or continent neobladder) is the standard of care. Inguinal lymph node dissection is performed for anterior urethral cancers with palpable inguinal nodes. Concurrent cisplatin-based chemoradiation with external beam radiotherapy is an alternative sphincter-preserving approach for selected T2-T3 patients not suitable for radical surgery or wishing to avoid a urinary stoma. Immunotherapy (pembrolizumab, atezolizumab) and FGFR-targeted therapy (erdafitinib for FGFR3 mutations) offer systemic options for platinum-refractory advanced urothelial-histology urethral cancer based on bladder cancer data.

Prevention of urethral cancer focuses on reducing exposure to known aetiological factors and managing modifiable risk conditions. HPV vaccination with Gardasil 9 targeting HPV 16/18 and other high-risk HPV types provides protection against HPV-related urethral SCC, as the virus is implicated in anterior urethral squamous carcinogenesis; vaccination is recommended at ages 9-26 years. Practising safe sex, including correct and consistent condom use, reduces the risk of HPV and other sexually transmitted infections that promote chronic urethral inflammation. Prompt and complete treatment of urethral strictures — whether from infectious, traumatic, or iatrogenic causes — eliminates the chronic inflammatory carcinogenic environment and is important secondary prevention. Urethral diverticula, detected on MRI or urethrocystoscopy, should be surgically repaired not only to resolve symptoms but also to eliminate the risk of adenocarcinoma developing within the diverticular pouch. Bladder cancer patients with preserved urethra following cystectomy require lifelong urethral surveillance by periodic urethroscopy and urine cytology. Smoking cessation reduces the risk of urothelial-type urethral carcinoma, which shares bladder cancer risk factor pathways. Minimising urethral catheterisation, ensuring aseptic technique when catheterisation is required, and using appropriately sized catheters reduces the risk of traumatic urethritis and stricture formation.

Any blood in the urine — regardless of volume or whether it is visible (frank haematuria) or microscopic (detected on dipstick or urinalysis) — requires prompt urological evaluation, as haematuria is the most common initial symptom of urethral cancer and other urological malignancies. Do not attribute haematuria to a urinary tract infection without complete resolution and documentation of haematuria clearance with appropriate antibiotic treatment, as urethral cancer frequently presents with concurrent infection masking the underlying pathology. Persistent urethral symptoms — dysuria, urinary frequency, poor stream, or urethral discharge — that do not resolve after adequate treatment for a suspected infection (UTI or STI) within 2 weeks require urological evaluation including urine culture, urethroscopy, and urethral swabs. A palpable urethral or periurethral lump in either sex requires urgent urological referral for examination, urethroscopy, and MRI. Bladder cancer patients with preserved urethra after cystectomy who develop any urethral discharge or haematuria must be urgently evaluated for urethral recurrence by their urologist. Any female patient with recurrent urinary tract infections, urethral pain, or a palpable anterior vaginal wall mass should be evaluated for urethral carcinoma arising in a urethral diverticulum. Given the rarity of this cancer and the diagnostic delay that commonly occurs, patients with persistent unexplained urethral symptoms should request specialist urology review.

Anterior urethral cancer: 5-year OS approximately 50-60%. Posterior urethral cancer: 5-year OS approximately 25-35%. Overall 5-year survival approximately 40% across all stages, reflecting late-stage presentation and limited clinical trial data due to rarity. Lymph node involvement significantly worsens prognosis, reducing 5-year survival to approximately 10-15%. Multimodal treatment combining neoadjuvant chemotherapy with radical surgery offers the best outcomes for advanced disease. The prognosis for Urethral Cancer - Symptoms, Diagnosis, and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.